Recommendations for the use of slow-release oral morphine as opioid agonist therapy
Evidence, Guidelines and Recommendations
Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).
Find 15 specialty-specific recommendations for when the use of opioids should not be first line therapy and information resources to help patients have informed conversations with their clinicians about safe options for managing pain.
Find 15 specialty-specific recommendations for when the use of opioids should not be first line therapy and information resources to help patients have informed conversations with their clinicians about safe options for managing pain.
